1. Elasticity Values as a Predictive Modality for Response to Neoadjuvant Chemotherapy in Breast Cancer.
- Author
-
Kim, Min Ji, Eun, Na Lae, Ahn, Sung Gwe, Kim, Jee Hung, Youk, Ji Hyun, Son, Eun Ju, Jeong, Joon, Cha, Yoon Jin, and Bae, Soong June
- Subjects
- *
RESEARCH , *ULTRASONIC imaging , *CONFIDENCE intervals , *CANCER chemotherapy , *CELL receptors , *METASTASIS , *CANCER patients , *COMPARATIVE studies , *LYMPHOCYTES , *DESCRIPTIVE statistics , *RESEARCH funding , *COMBINED modality therapy , *TUMOR markers , *STATISTICAL correlation , *ODDS ratio , *BREAST tumors - Abstract
Simple Summary: Although shear-wave elastography has been utilized in diagnosing a malignant breast lesion and axillary lymph node metastasis, its potential role in predicting treatment response to neoadjuvant chemotherapy has not been thoroughly explored. In this study, we aimed to assess the possibility of elasticity values measured using SWE as a predictive marker for neoadjuvant chemotherapy in breast cancer. Our findings indicate that low tumor stiffness, as measured using SWE, was significantly associated with an excellent treatment response following neoadjuvant chemotherapy. This relationship was particularly evident in hormone-receptor-positive, HER2-negative breast cancer, and triple-negative breast cancer. Furthermore, we identified an inverse correlation between tumor stiffness and the tumor-infiltrating lymphocyte level, suggesting that tumors with high TIL levels tend to exhibit lower stiffness. Our findings suggest that SWE could be a useful tool in predicting treatment response and guiding treatment decisions in neoadjuvant chemotherapy for patients with breast cancer. Shear-wave elastography (SWE) is an effective tool in discriminating malignant lesions of breast and axillary lymph node metastasis in patients with breast cancer. However, the association between the baseline elasticity value of breast cancer and the treatment response of neoadjuvant chemotherapy is yet to be elucidated. Baseline SWE measured mean stiffness (E-mean) and maximum stiffness (E-max) in 830 patients who underwent neoadjuvant chemotherapy and surgery from January 2012 to December 2022. Association of elasticity values with breast pCR (defined as ypTis/T0), pCR (defined as ypTis/T0, N0), and tumor-infiltrating lymphocytes (TILs) was analyzed. Of 830 patients, 356 (42.9%) achieved breast pCR, and 324 (39.0%) achieved pCR. The patients with low elasticity values had higher breast pCR and pCR rates than those with high elasticity values. A low E-mean (adjusted odds ratio (OR): 0.620; 95% confidence interval (CI): 0.437 to 0.878; p = 0.007) and low E-max (adjusted OR: 0.701; 95% CI: 0.494 to 0.996; p = 0.047) were independent predictive factors for breast pCR. Low elasticity values were significantly correlated with high TILs. Pretreatment elasticity values measured using SWE were significantly associated with treatment response and inversely correlated with TILs, particularly in HR+HER2- breast cancer and TNBC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF